We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Novo Nordisk | NYSE:NVO | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.03 | -0.81% | 125.85 | 9,335 | 11:29:59 |
From Apr 2019 to Apr 2024
By Stephen Nakrosis
The U.S. Food and Drug Administration said Monday it approved a treatment made by Novo Nordisk A/S to treat pediatric patients with type 2 diabetes.
The FDA said Novo's Victoza, or liraglutide, injection is the first non-insulin drug approved to treat type 2 diabetes in pediatric patients since 2000. The treatment was approved for pediatric patients 10 years or older with type 2 diabetes, and has been approved to treat adult patients with type 2 diabetes since 2010.
Lisa Yanoff, acting director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research, said: "Victoza has now been shown to improve blood sugar control in pediatric patients with type 2 diabetes. The expanded indication provides an additional treatment option at a time when an increasing number of children are being diagnosed with this disease."
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
June 17, 2019 15:57 ET (19:57 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Novo Nordisk Chart |
1 Month Novo Nordisk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
